Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;95(6):627-35.
doi: 10.1038/clpt.2014.20. Epub 2014 Jan 31.

Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy

D S Campo  1 , P Skums  1 , Z Dimitrova  1 , G Vaughan  1 , J C Forbi  1 , C G Teo  1 , Y Khudyakov  1 , D T-Y Lau  2
Affiliations

Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy

D S Campo et al. Clin Pharmacol Ther. 2014 Jun.

Abstract

Using hepatitis C virus (HCV) and interferon (IFN) resistance as a proof of concept, we have devised a new method for calculating the effect of a drug on a viral population, as well as the resistance of the population's individual intrahost variants. By means of next-generation sequencing, HCV variants were obtained from sera collected at nine time points from 16 patients during the first 48 h after injection of IFN-α. IFN-resistance coefficients were calculated for individual variants using changes in their relative frequencies, and for the entire intrahost viral population using changes in viral titer. Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-α2a/ribavirin treatment outcome at week 12 (P = 3.78 × 10(-5) and 0.0114, respectively). This new method allows an accurate measurement of resistance based solely on changes in viral titer or the relative frequency of intrahost viral variants during a short observation time.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors disclose no conflicts.

Figures

Figure 1
Figure 1
HCV RNA level across all time-points. Patients are grouped according to treatment outcomes.
Figure 2
Figure 2
A) Number of patients by IL28B status and therapy outcome. B) Population IFN-resistance for each patient. Blue: RVR; red: cEVR; yellow: pEVR; and green: NR. C) Average population IFN-resistance of patients for each outcome, bars correspond to standard error of the mean. D) Number of reads obtained by NGS from each patient and each time-point.
Figure 3
Figure 3
Relative frequencies of persistent variants over time in all patients.
Figure 4
Figure 4
Average IFN-resistance calculated over the patients of each therapy outcome. A) Number of IFN-resistant variants. B) IFN-resistance coefficient of the major variant. C) Fraction of the total number of reads that are IFN-resistant. D) Maximum IFN-resistance found. Bars correspond to standard error of the mean.
Figure 5
Figure 5
Maximum likelihood trees of all the sequences from patients with resistant variants. Red: IFN-resistant variants; blue: IFN-sensitive variants.
See this image and copyright information in PMC

References

    1. Said Z, Abdelwahab K. Viral Replication. InTech; 2013. pp. 127–144. ed. D. 10.5772/53707.
    1. Zambon MC. Surveillance for antiviral resistance. Influenza and other respiratory viruses. 2013;7 Suppl 1:37–43. - PMC - PubMed
    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2012 - PubMed
    1. Hsu CS, et al. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007;50:310–315. - PubMed
    1. Aghemo A, Rumi MG, Colombo M. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert review of anti-infective therapy. 2009;7:925–935. - PubMed

Publication types

MeSH terms